These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 30001523)

  • 1. Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.
    Ernst JD
    Cell Host Microbe; 2018 Jul; 24(1):34-42. PubMed ID: 30001523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology of
    Sia JK; Rengarajan J
    Microbiol Spectr; 2019 Jul; 7(4):. PubMed ID: 31298204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stealth Strategies of
    Naeem MA; Ahmad W; Tyagi R; Akram Q; Younus M; Liu X
    Curr Issues Mol Biol; 2021; 41():597-616. PubMed ID: 33068079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond memory T cells: mechanisms of protective immunity to tuberculosis infection.
    Steigler P; Verrall AJ; Kirman JR
    Immunol Cell Biol; 2019 Aug; 97(7):647-655. PubMed ID: 31141205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium tuberculosis infection and vaccine development.
    Tang J; Yam WC; Chen Z
    Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The generation of T-cell memory to protect against tuberculosis.
    Counoupas C; Triccas JA
    Immunol Cell Biol; 2019 Aug; 97(7):656-663. PubMed ID: 31127962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against
    Chen Y; Xiao JN; Li Y; Xiao YJ; Xiong YQ; Liu Y; Wang SJ; Ji P; Zhao GP; Shen H; Lu SH; Fan XY; Wang Y
    Front Immunol; 2018; 9():3190. PubMed ID: 30700988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of new tuberculosis vaccine in children.
    Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
    Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current status, challenges, and future developments of new tuberculosis vaccines.
    Gong W; Liang Y; Wu X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1697-1716. PubMed ID: 29601253
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ryndak MB; Laal S
    Front Cell Infect Microbiol; 2019; 9():299. PubMed ID: 31497538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering protective immunity against tuberculosis: implications for vaccine development.
    Counoupas C; Triccas JA; Britton WJ
    Expert Rev Vaccines; 2019 Apr; 18(4):353-364. PubMed ID: 30793629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant live vaccine candidates against tuberculosis.
    Kaufmann SH; Gengenbacher M
    Curr Opin Biotechnol; 2012 Dec; 23(6):900-7. PubMed ID: 22483201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of phthiocerol dimycocerosate on CD4(+) T cell priming and persistence during Mycobacterium tuberculosis infection.
    Pinto R; Nambiar JK; Leotta L; Counoupas C; Britton WJ; Triccas JA
    Tuberculosis (Edinb); 2016 Jul; 99():25-30. PubMed ID: 27450001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J; Doherty TM
    APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of clinical models for the evaluation of human TB vaccines.
    O'Shea MK; McShane H
    Hum Vaccin Immunother; 2016 May; 12(5):1177-87. PubMed ID: 26810964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the host immune response to tuberculosis vaccines.
    Fletcher HA
    Vaccine; 2015 Sep; 33(40):5313-5. PubMed ID: 26241949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis Vaccine Development: Progress in Clinical Evaluation.
    Sable SB; Posey JE; Scriba TJ
    Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31666281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.